Curis Inc (CRIS) stock
CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/3094% below fair value
$0.44−0.01 (-2.07%)
Close on Nov 16, 2026Market cap $910.86KP/E –Yield –
Curis price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Curis's price to sales ratio was 0.3× on Nov 11, 2026, against 1.5× a year earlier. Over the last 5 years it ranged from 0.3× to 41.4×, with a median of 3.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.3× | −0.8 |
| 2025 | Dec 31, 2025 | 1.1× | −0.7 |
| 2024 | Dec 31, 2024 | 1.8× | −5.6 |
| 2023 | Dec 29, 2023 | 7.3× | +2.3 |
| 2022 | Dec 30, 2022 | 5.1× | −36.3 |
| 2021 | Dec 31, 2021 | 41.4× | −0.4 |
| 2020 | Dec 31, 2020 | 41.8× | +35.8 |
| 2019 | Dec 31, 2019 | 6.0× | +3.9 |
| 2018 | Dec 31, 2018 | 2.1× | −10.7 |
| 2017 | Dec 29, 2017 | 12.8× | −46.7 |
| 2016 | Dec 30, 2016 | 59.4× | +11.4 |
| 2015 | Dec 31, 2015 | 48.0× | +34.3 |
| 2014 | Dec 31, 2014 | 13.8× | −1.9 |
| 2013 | Dec 31, 2013 | 15.6× | +6.3 |
| 2012 | Dec 31, 2012 | 9.3× | −453.8 |
| 2011 | Dec 30, 2011 | 463.1× | – |
See a number that looks wrong?